As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including ...

Researchers have seen an 'alarming' rise in breast cancer rates in women under 40, with some states experiencing a 32% ...

Imaging technology developed and refined at the University of Waterloo promises better detection and treatment of breast cancer by more accurately pinpointing cancerous tissue.

A Lowcountry woman who beat breast cancer is now dedicating her life to raising awareness about the disease and its warning ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit offers insight into the new NCCN guidelines, discusses the new ...

Doctors are hoping a clinical trial at Harris Health Ben Taub will prove the treatment works and it’s worth getting ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...